Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
On Sept. 8, 2025, Pfizer and BioNTech announced positive topline results from an ongoing Phase 3 clinical trial…